FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate ...
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV -
United States Weston Miller Shawnm Cox Drug Administration Corporate Communications Media Contact Lisa Orphan Drug Designation
Source: eagletribune.com